Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The endogenous nitrate- and nitrite-reducing enzymatic systems constitute a secondary pathway for nitric oxide (NO) production that operates independently of the oxygen-dependent nitric oxide synthase (NOS) enzymes (Lundberg et al., 2008). This pathway involves the sequential reduction of nitrate to nitrite, primarily by commensal oral bacteria, and the subsequent reduction of nitrite to NO by various mammalian proteins (Gladwin et al., 2005). Key enzymes and proteins involved in this process include xanthine oxidoreductase, deoxyhemoglobin, deoxymyoglobin, and certain mitochondrial enzymes (Weitzberg et al., 2010). A unique feature of this system is that its activity is significantly enhanced under conditions of hypoxia and low pH, where the conventional NOS pathway is often impaired (Zweier et al., 1995). In disease states such as hypertension, myocardial infarction, and peripheral artery disease, these systems serve as a crucial backup for maintaining NO bioavailability and vascular homeostasis (Hord et al., 2009). Therapeutic interventions often involve the administration of inorganic nitrate or nitrite salts to provide substrates for these enzymes, thereby promoting vasodilation and cytoprotection. Research into these systems has expanded the understanding of how dietary nitrate influences cardiovascular health and exercise performance. However, pharmacological targeting must be carefully managed to avoid excessive NO production or the formation of methemoglobin.
The primary mechanism involves the enzymatic reduction of inorganic nitrate to nitrite and then to nitric oxide (NO), providing an alternative source of NO that is particularly active during hypoxia and acidosis, thereby bypassing dysfunctional nitric oxide synthase (NOS) pathways (Lundberg et al., 2008).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endogenous nitrate- and nitrite-reducing enzymatic systems (Nitrate-nitrite-NO pathway).